An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences. A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment when compared with older drugs for the blood borne virus. The vote was part of a broader review of new hepatitis C drugs by the California Technology Assessment Forum. The insurer-affiliated group assesses the costs and effectiveness of new medical treatments. The group estimates that replacing currently used hepatitis C drugs with Gilead's Sovaldi would raise California drug costs between $18 billion and $29 billion per year. The drug costs $84,000 for one 12-week course of treatment.
Read More at: http://13wham.com//news/features/top-stories/stories/new-hepatitis-c-drug-worth-1000-pill-10192.shtml?
Read More at: http://13wham.com//news/features/top-stories/stories/new-hepatitis-c-drug-worth-1000-pill-10192.shtml?
No comments:
Post a Comment